A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Eli Lilly and Company · NCT07759245
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 40–75 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 606
- US sites recruiting
- 14
- Study start
- August 7, 2026
- Record last updated
- October 8, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when compared with placebo. The study will last approximately one year.
Being studied: Brenipatide; Placebo; Standard of Care
Conditions: Pulmonary Disease, Chronic Obstructive
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Have a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD), at least 12 months prior to screening who meet the following criteria:
- Current or former smokers with a smoking history of greater than or equal to (≥) 10 pack-years
- Moderate-to-severe COPD (post-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV₁)/forced vital capacity (FVC) less than (\<) 70 percent (%)
- Modified Medical Research Council Dyspnea Scale (mMRC-DS) grade ≥2
- Exacerbation history of ≥2 moderate or ≥1 severe exacerbations within the year prior to inclusion.
- Background double therapy [long-acting β₂-agonists (LABA) + long-acting muscarinic antagonists (LAMA)] or triple therapy [inhaled corticosteroids (ICS) + LABA + LAMA)] for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to screening.
Exclusion Criteria
- Have a known pre-existing, clinically important lung condition other than COPD.
- Have a current or recent acute, active infection before screening and up to randomization.
Recruiting US locations
University of Alabama at Birmingham
Birmingham, AL 35233
Site contact: 484-707-6813
NewportNativeMD, Inc.
Newport Beach, CA 92663
Site contact: 949-791-8599
Institute of HealthCare Assessment d/b/a Apex Clinical Research
San Diego, CA 92120
Site contact: 619-582-5564
Millennium Medical Research - Miami
Miami, FL 33126
Site contact: David Orta
Deluxe Health Center
Miami Lakes, FL 33014
Site contact: 305-209-1268
Florida Institute For Clinical Research, LLC
Orlando, FL 32825
Site contact: 407-658-0966
Axis Clinical Trials - Westchester
Westchester, IL 60154
Site contact: Mohammad Ghani
Indiana University Health University Hospital
Indianapolis, IN 46202
Site contact: 317-278-0099
IU Health Ball Memorial Hospital, Inc.
Muncie, IN 47303
Site contact: Sashank Kolli
Revive Research Institute, Inc.
Southfield, MI 48075
Site contact: 248-829-3103
Headlands Research-Twin Cities
Maplewood, MN 55109
Site contact: Charlene McEvoy
Clinical Research Associates of Central PA
DuBois, PA 15801
Site contact: 814-940-1212
Prime Clinical Research - Lewisville
Lewisville, TX 75067
Site contact: 817-907-7330
Paramount Clinical Research - Data Point Clinical Research
Kirkland, WA 98034
Site contact: 425-577-1107
Study contacts (from the official record)
- Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
- Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com